HK1168387A1 - Methods for breast cancer risk assessment - Google Patents

Methods for breast cancer risk assessment

Info

Publication number
HK1168387A1
HK1168387A1 HK12109000.5A HK12109000A HK1168387A1 HK 1168387 A1 HK1168387 A1 HK 1168387A1 HK 12109000 A HK12109000 A HK 12109000A HK 1168387 A1 HK1168387 A1 HK 1168387A1
Authority
HK
Hong Kong
Prior art keywords
methods
breast cancer
risk assessment
cancer risk
assessment
Prior art date
Application number
HK12109000.5A
Other languages
English (en)
Chinese (zh)
Inventor
David A Hinds
Bryan Walser
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of HK1168387A1 publication Critical patent/HK1168387A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
HK12109000.5A 2009-06-01 2012-09-13 Methods for breast cancer risk assessment HK1168387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18280909P 2009-06-01 2009-06-01
US25842009P 2009-11-05 2009-11-05
PCT/AU2010/000675 WO2010139006A1 (en) 2009-06-01 2010-06-01 Methods for breast cancer risk assessment

Publications (1)

Publication Number Publication Date
HK1168387A1 true HK1168387A1 (en) 2012-12-28

Family

ID=43297192

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109000.5A HK1168387A1 (en) 2009-06-01 2012-09-13 Methods for breast cancer risk assessment

Country Status (13)

Country Link
US (2) US20110294681A1 (xx)
EP (1) EP2438193B1 (xx)
JP (1) JP5976533B2 (xx)
CN (1) CN102712949B (xx)
AU (1) AU2010256343B2 (xx)
BR (1) BRPI1011979A2 (xx)
CA (1) CA2763500C (xx)
DK (1) DK2438193T3 (xx)
ES (1) ES2546230T3 (xx)
HK (1) HK1168387A1 (xx)
IL (1) IL216627A (xx)
MX (1) MX2011012913A (xx)
WO (1) WO2010139006A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
CN101535500B (zh) 2005-11-29 2013-12-11 剑桥企业有限公司 乳腺癌标志物
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
EP2438193B1 (en) 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US10437858B2 (en) 2011-11-23 2019-10-08 23Andme, Inc. Database and data processing system for use with a network-based personal genetics services platform
EP2904398B1 (en) * 2012-10-02 2018-04-11 SphingoTec GmbH A method for predicting the risk of getting cancer in a female subject
CN103966310A (zh) * 2014-01-27 2014-08-06 广州市体育科学研究所 乳腺癌易感基因快速检测试剂盒及检测方法
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US20160102358A1 (en) * 2014-10-14 2016-04-14 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with cancer risk
AU2016368696B2 (en) * 2015-12-07 2021-11-25 Ontario Institute For Cancer Research (Oicr) Gene signature of residual risk following endocrine treatment in early breast cancer
SG11201906778RA (en) * 2017-01-24 2019-08-27 Genetic Tech Limited Improved methods for assessing risk of developing breast cancer
JP6935079B2 (ja) * 2017-05-09 2021-09-15 国立大学法人千葉大学 機能的snpの組合せ解析
US11861491B2 (en) * 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
JP6961725B2 (ja) 2017-10-16 2021-11-05 イルミナ インコーポレイテッド 深層畳み込みニューラルネットワークのアンサンブルを訓練するための半教師あり学習
US11081217B2 (en) * 2017-12-21 2021-08-03 Basehealth, Inc. Systems and methods for optimal health assessment and optimal preventive program development in population health management
EP3874510A4 (en) 2018-10-31 2022-08-03 Ancestry.com DNA, LLC ESTIMATION OF PHENOTYPES USING DNA, PEDIGREE AND HISTORICAL DATA
CN109971856A (zh) * 2019-04-15 2019-07-05 无锡芯超生物科技有限公司 用于评估人类受检者罹患肺癌的试剂盒或系统及应用
WO2021078794A1 (en) 2019-10-22 2021-04-29 Sistemas Genómicos, S.L. In vitro method for determining the risk of developing breast cancer in a subject
CN113299400B (zh) * 2021-06-23 2023-02-21 复旦大学附属儿科医院 新生儿危重症遗传风险评估方法、装置及设备

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4240602A (en) 1979-03-19 1980-12-23 The Babcock & Wilcox Company Support device for a pressure vessel
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US6355427B1 (en) 1996-11-07 2002-03-12 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
CA2350069A1 (en) 1998-12-02 2000-06-08 Hugh Y. Rienhoff, Jr. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) * 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
AU2001280752A1 (en) 2000-07-25 2002-02-05 Dzgenes, L.L.C. Diagnostic polymorphisms for the ecnos promoter
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US20040002071A1 (en) 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
WO2005014846A2 (en) 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050136438A1 (en) 2003-09-04 2005-06-23 David Ralph Genetic analysis for stratification of cancer risk
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
CN101535500B (zh) 2005-11-29 2013-12-11 剑桥企业有限公司 乳腺癌标志物
EP2207895A2 (en) * 2006-06-23 2010-07-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
EP2102651A4 (en) * 2006-11-30 2010-11-17 Navigenics Inc GENERALYSIS SYSTEMS AND METHODS
MX2009010439A (es) * 2007-03-26 2009-10-20 Decode Genetics Ehf Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
AU2008256219B2 (en) * 2007-05-25 2014-06-05 Decode Genetics Ehf. Genetic variants on Chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2176426A2 (en) * 2007-07-11 2010-04-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
WO2010017520A1 (en) * 2008-08-08 2010-02-11 Navigenics, Inc. Methods and systems for personalized action plans
KR20110074527A (ko) * 2008-09-12 2011-06-30 네이비제닉스 인크. 복수의 환경 및 유전 위험 인자를 통합하기 위한 방법 및 시스템
EP2438193B1 (en) 2009-06-01 2015-07-22 Genetic Technologies Limited Methods for breast cancer risk assessment
WO2013151413A1 (en) 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
EP3201360A4 (en) 2014-09-30 2018-05-09 Genetic Technologies Limited Methods for assessing risk of developing breast cancer

Also Published As

Publication number Publication date
US20110294681A1 (en) 2011-12-01
WO2010139006A1 (en) 2010-12-09
AU2010256343B2 (en) 2014-01-30
CN102712949B (zh) 2015-12-16
US20180080089A1 (en) 2018-03-22
CA2763500A1 (en) 2010-12-09
EP2438193A1 (en) 2012-04-11
AU2010256343A1 (en) 2011-12-22
EP2438193A4 (en) 2012-11-21
JP2012528573A (ja) 2012-11-15
IL216627A (en) 2016-08-31
US11072830B2 (en) 2021-07-27
CA2763500C (en) 2019-09-03
MX2011012913A (es) 2012-02-21
CN102712949A (zh) 2012-10-03
DK2438193T3 (en) 2015-10-19
BRPI1011979A2 (pt) 2020-10-06
EP2438193B1 (en) 2015-07-22
ES2546230T3 (es) 2015-09-21
IL216627A0 (en) 2012-02-29
JP5976533B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
HK1168387A1 (en) Methods for breast cancer risk assessment
ZA201205003B (en) Methods for treating breast cancer
HK1175476A1 (en) Cancer treatment
EP2613151A4 (en) METHOD OF DETERMINING THE APPEARANCE OF CANCER OR THE RISK OF APPEARANCE OF CANCER
EP2585833A4 (en) METHODS OF DETECTING CANCER
IL225441A0 (en) Breast cancer diagnostics
EP2423323A4 (en) METHOD OF TUMOR ASSESSMENT
IL210504A0 (en) Genetic variants for breast cancer risk assessment
EP2382331A4 (en) KREBSBIOMARKER
HUS2300023I1 (hu) Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
GB201016139D0 (en) Cancer phosholipidome
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
IL222958A0 (en) Cancer treatment
EP2524702A4 (en) DIAGNOSTIC TO CANCER
GB201012590D0 (en) Methods for diagnosing cancer
EP2515114A4 (en) METHOD FOR THE DIAGNOSIS OF MALIGNANT TUMOR
GB201016411D0 (en) In vivo imaging method for cancer
EP2391211A4 (en) METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER
PT2467140T (pt) Lapatinib para tratamento do cancro
GB0906100D0 (en) Prediscover breast cancer detection aid
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy
GB201019034D0 (en) Treatment for tumors
GB201019101D0 (en) Heating apparatus for breasts